Friday - July 11, 2025
RESEARCH TRIANGLE PARK, N.C., June 12, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 24, 2023 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders held in New York, New York on June 12, 2023.
Detailed results of the vote for the election of directors are set out below:
Name of Nominee | Votes For | % Votes For | Votes Withheld | % Votes Withheld |
Dr. Khalid Islam | 15,932,888 | 99.61% | 61,730 | 0.38% |
Mr. Adrian Haigh | 15,931,496 | 99.60% | 63,122 | 0.39% |
Mr. Chris A. Rallis | 15,931,887 | 99.60% | 62,731 | 0.39% |
Mr. Marco Brughera | 15,935,618 | 99.63% | 59,000 | 0.36% |
Dr. Jodi Cook | 15,932,047 | 99.60% | 62,571 | 0.39% |
Mr. Rostislav Raykov | 15,924,786 | 99.56% | 69,832 | 0.43% |
Shareholders voted 99.25% in favour of appointing Haskell & White LLP as auditors and authorizing the directors to fix the auditor remuneration, 99.13% in favour of the compensation paid to the Company’s named executive officers.
The Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq, and accordingly did not seek shareholder re-approval for the unallocated shares under its long-term equity inventive plan at this year’s Annual General Meeting.
For further information, please contact:
Rosty Raykov
Chief Executive Officer
Fennec Pharmaceuticals Inc.
T: (919) 636-5144
Last Trade: | US$8.78 |
Daily Change: | -0.26 -2.88 |
Daily Volume: | 166,342 |
Market Cap: | US$242.500M |
May 13, 2025 March 10, 2025 December 20, 2024 November 07, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load